PMC9635034_01
(A), (B) BM smears obtained at the diagnosis of AML showed erythroid proliferation with myeloblasts (arrows) and micromegakaryocytes (arrowhead). (C) A tumor biopsy performed at the diagnosis of DLBCL showed diffuse proliferation of large lymphoma cells with many tingible body macrophages. (D) CD20 staining, (E) BCL6 staining, (F) MYC staining. (G) BM smear at the diagnosis of DLBCL revealed the infiltration of atypical large lymphoid cells.
jslrt-62-175-g001.jpg
PMC9635034_02_jslrt-62-175-g001.jpg
f1
An abdominal biopsy specimen demonstrated diffuse proliferation of large atypical lymphoid cells (Figure 1C). These cells were immunohistochemically positive for CD10 (weak), CD20 (Figure 1D), CD79a, and BCL6 (Figure 1E), and negative for CD3, CD5, BCL2, and MUM1. Immunohistochemical staining showed that 60% of the tumors cells were positive for MYC (Figure 1F) and 90% were positive for Ki-67, whereas in situ hybridization with EBV-encoded small nuclear early region 1 (EBER 1 ISH) produced negative results. BM aspiration revealed the infiltration of lymphoma cells (frequency: 0.4%) (Figure 1G), G-banding analysis showed complicated abnormalities including t(8;14)(q24;q32), and FISH analysis revealed an IGH/MYC rearrangement frequency of 5% and was negative for KMT2A (Table 1).
PMC9635034_02
(A), (B) BM smears obtained at the diagnosis of AML showed erythroid proliferation with myeloblasts (arrows) and micromegakaryocytes (arrowhead). (C) A tumor biopsy performed at the diagnosis of DLBCL showed diffuse proliferation of large lymphoma cells with many tingible body macrophages. (D) CD20 staining, (E) BCL6 staining, (F) MYC staining. (G) BM smear at the diagnosis of DLBCL revealed the infiltration of atypical large lymphoid cells.
jslrt-62-175-g001.jpg
PMC9635034_02_jslrt-62-175-g001.jpg
f1
An abdominal biopsy specimen demonstrated diffuse proliferation of large atypical lymphoid cells (Figure 1C). These cells were immunohistochemically positive for CD10 (weak), CD20 (Figure 1D), CD79a, and BCL6 (Figure 1E), and negative for CD3, CD5, BCL2, and MUM1. Immunohistochemical staining showed that 60% of the tumors cells were positive for MYC (Figure 1F) and 90% were positive for Ki-67, whereas in situ hybridization with EBV-encoded small nuclear early region 1 (EBER 1 ISH) produced negative results. BM aspiration revealed the infiltration of lymphoma cells (frequency: 0.4%) (Figure 1G), G-banding analysis showed complicated abnormalities including t(8;14)(q24;q32), and FISH analysis revealed an IGH/MYC rearrangement frequency of 5% and was negative for KMT2A (Table 1).
(A) 18F-FDG PET/CT performed at the diagnosis of DLBCL showed an abdominal tumor, and (B) the abnormal 18F-FDG uptake disappeared after 4 cycles of DA-EPOCH-R treatment.
jslrt-62-175-g002.jpg
PMC9635034_03_jslrt-62-175-g002.jpg
f2
After 4 cycles of DA-EPOCH-R, he was confirmed to be in metabolic CR by PET/CT (Figure 2B), his BM showed a normal karyotype during G-banding analysis, and FISH analysis demonstrated that he was negative for IGH/MYC.
PMC9635034_03
(A) 18F-FDG PET/CT performed at the diagnosis of DLBCL showed an abdominal tumor, and (B) the abnormal 18F-FDG uptake disappeared after 4 cycles of DA-EPOCH-R treatment.
jslrt-62-175-g002.jpg
PMC9635034_03_jslrt-62-175-g002.jpg
f2
After 4 cycles of DA-EPOCH-R, he was confirmed to be in metabolic CR by PET/CT (Figure 2B), his BM showed a normal karyotype during G-banding analysis, and FISH analysis demonstrated that he was negative for IGH/MYC.